TrialBlood2025

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.

Lorenzo Falchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.